Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Short interest in Editas Medicine Inc (NASDAQ:EDIT) decreased during the last reporting period, falling from 18.96M to 16.74M. This put 25.72% of the company's publicly available shares short.